Frederick L. Ruberg, MD
Frederick L. Ruberg, MD is an Associate Professor of Medicine and Radiology at Boston University (BU) School of Medicine and clinical cardiologist at Boston Medical Center (BMC), specializing in cardiac imaging and infiltrative heart disease. He attended the University of Pennsylvania School of Medicine, completed internal medicine training at Brigham and Women’s Hospital, cardiovascular disease fellowship at Boston Medical Center/Boston University School of Medicine, and a fellowship in cardiovascular magnetic resonance imaging at Beth Israel Deaconess Medical Center.
Dr. Ruberg has an active clinical practice as the senior cardiologist in the BU/BMC Amyloidosis Center. He is Associate Chief of Cardiovascular Medicine for Academic Affairs, Associate Director of the Cardiovascular Medicine Fellowship program, director of the cardiac MRI program at BMC as well as the Integrated Pilot Grants Program of the Boston University Clinical and Translational Science Institute.
Dr. Ruberg is also an Associate Editor of Circulation: Cardiovascular Imaging and a Fellow of the American Heart Association and American College of Cardiology. His NIH and industry funded research program focuses on the application of non-invasive cardiac imaging for amyloidosis identification and clinical care optimization. Dr. Ruberg’s active area of research interest is ATTR amyloidosis. Current projects involve the application of pyrophosphate imaging for detection of ATTR amyloidosis, application of echocardiographic strain imaging as a disease marker, evaluation of treatments of ATTR amyloidosis, and validation of point of care diagnostic tools for cardiac amyloidosis identification in the outpatient clinic. Dr. Ruberg is committed to raising awareness of cardiac amyloidosis among clinicians and the general population so as to afford early diagnosis and enhanced access to disease modifying therapies.
Representative Publications:
Expert Analysis and Opinion—Understanding Cardiac Amyloidosis
Lay Summary of “Expert Analysis and Opinion—Understanding Cardiac Amyloidosis”
Early Detection of Multiorgan Light Chain (AL) Amyloidosis by Whole Body 18F-florbetapir PET/CT
Early Diagnosis of Cardiac Amyloidosis by Carpal Tunnel Surgery: Is it All in the Wrist?
Development and Validation of a Survival Staging System Incorporating Bnp in Patients With Light Chain Amyloidosis
Echocardiography and Survival in Light Chain Cardiac Amyloidosis: Back to Basics
Monoclonal Gammopathy of Undetermined Significance in Systemic Transthyretin Amyloidosis (ATTR)
